Canavan disease (CD) has only been diagnosed on autopsy or brain biops
y, however, specific biochemical markers, such as N-acetylaspartic aci
d (NAA) and aspartoacylase activity, have recently been described in C
D. We report a case of CD having the above biochemical markers. High l
evels of NAA were found in her urine, serum and CSF. Fibroblasts did n
ot exhibit aspartoacylase activity. Clinically, she presented progress
ive psychomotor retardation, cerebellar signs, pyramidal signs and rel
ative megalencephaly. CT and MRI showed findings of leukodystrophy. Th
e evoked potentials showed widespread involvement in the brainstem. Ma
gnetic resonance spectra showed a high level of NAA in the white matte
r. In Japan, this case is the first of CD determined on the basis of b
iochemical markers.